Assessing the COVID-19 vaccination program during the Omicron variant (B.1.1.529) epidemic in early 2022, Tokyo

BMC Infectious Diseases

Table 2 Total number of averted SARS-CoV-2 infections attributable to a vaccination program by age group

Age group (years)	Vaccine dose^a	Averted cases (95% confidence interval)	Relative change (%)^b
0–9	Primary series and booster	1,375,249 (1,369,273–1,381,905)	-46.6
0–9	Booster	1,425,061 (1,418,927–1,431,610)	-48.4
10–19	Primary series and booster	1,324,726 (1,317,489–1,331,570)	-55.8
10–19	Booster	1,268,196 (1,261,495–1,274,982)	-53.8
20–29	Primary series and booster	2,264,996 (2,250,867–2,280,054)	-61.2
20–29	Booster	2,411,696 (2,398,716–2,424,445)	-63.5
30–39	Primary series and booster	2,267,999 (2,254,956–2,283,361)	-64.0
30–39	Booster	2,392,823 (2,378,472–2,407,955)	-65.9
40–49	Primary series and booster	2,265,627 (2,252,443–2,280,210)	-66.6
40–49	Booster	2,340,664 (2,323,896–2,357,358)	-67.7
50–59	Primary series and booster	1,530,498 (1,518,872–1,544,057)	-71.9
50–59	Booster	1,649,600 (1,634,595–1,664,511)	-73.9
60–69	Primary series and booster	842,916 (835,277–850,903)	-76.8
60–69	Booster	894,544 (883,907–904,551)	-78.1
70–79	Primary series and booster	630,597 (624,516–637,241)	-79.3
70–79	Booster	634,301 (626,165–642,737)	-79.4
≥80	Primary series and booster	636,801 (631,247–642,524)	-80.3
≥80	Booster	596,883 (589,711–603,884)	-79.0

^aPrimary series and booster represents the combined vaccination programs for the first, second, and third doses, and booster represents the vaccination program for the third dos
^bRelative change represents a comparison between the estimated counterfactual number of infections and the observed number of infections, considering a reporting coverage of 0.25

ISSN: 1471-2334